Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

PITTSBURGH - Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a biotech firm specializing in novel therapies for medical conditions lacking adequate treatments, has received FDA approval for an Expanded ...

The FDA’s approval for expanded use reinforces LP-310’s potential as a new therapeutic option for OLP and supports ongoing clinical development efforts.

Green Lobster CBD Gummies for pain and stress relief. Buy them from the official website for genuine quality and results.

Set to enter hospice care, a patient with idiopathic multicentric Castleman's disease is now in remission after treatment with a medication identified by an AI-guided analysis.

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD).

The outbreak marks Uganda's eighth from an Ebola virus. The first confirmed case in the outbreak was a nurse at a hospital in the nation's capital, Kampala, who contracted Ebola on Jan. 20 or Jan. 21 ...